- Puma to host investor/analyst meeting and webcast on June 1 -
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, announced the release of four abstracts on
its drug candidate PB272 (neratinib) that will be presented at the
American Society of Clinical Oncology (ASCO) Annual Meeting, which will
be held May 29 to June 2, 2015, in Chicago. Abstracts are available to
the public online on the ASCO website: www.abstract.asco.org:
|
|
|
|
Abstract #508:
|
|
Breast Cancer—HER2/ER, Oral Abstract Session
|
|
|
|
|
Abstract #610:
|
|
Breast Cancer—HER2/ER, Poster Session
|
|
|
|
|
Abstract #1085:
|
|
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy, Poster
Session
|
|
|
|
|
Abstract #1099:
|
|
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy, Poster
Session
|
Puma will host an investor/analyst meeting in Chicago to discuss its
clinical trial data presented at ASCO beginning at 7:00 p.m. CDT on
Monday, June 1. The meeting will be webcast live and available for
replay at www.pumabiotechnology.com/ir_events.html.
About Puma Biotechnology
Puma Biotechnology, Inc. is a development stage biopharmaceutical
company that acquires and develops innovative products for the treatment
of various forms of cancer. The Company focuses on in-licensing drug
candidates that are undergoing or have already completed initial
clinical testing for the treatment of cancer and then seeks to further
develop those drug candidates for commercial use. The Company is
initially focused on the development of PB272 (oral neratinib), a potent
irreversible tyrosine kinase inhibitor, for the treatment of patients
with HER2-positive breast cancer and patients with non-small cell lung
cancer, breast cancer and other solid tumors that have a HER2 mutation.
Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.
Forward-Looking Statements:
This press release contains forward-looking statements that involve
risks and uncertainties that could cause the Company's actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and actual
outcomes and results could differ materially from these statements due
to a number of factors, which include, but are not limited to, the risk
factors disclosed in the periodic reports filed by the Company with the
Securities and Exchange Commission from time to time. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. The Company assumes
no obligation to update these forward-looking statements, except as
required by law.
Contact: